ThermoTrex
This article was originally published in The Gray Sheet
Executive Summary
Nets $23.1 mil. from public offering of 1.61 mil. shares of common at $15.375, including 210,000 shares sold to underwriters NatWest Securities Limited and Lehman Brothers Inc. under an over-allotment provision. The breast cancer imaging and biopsy systems manufacturer will use the proceeds for "general corporate purposes, including the possible acquisition of one or more businesses," the firm states in a filing with the Securities and Exchange Commission ("The Gray Sheet" March 7, p. 12)
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.